BRUSSELS Mon Feb 24, 2014 1:35am EST
BRUSSELS Feb 24 (Reuters) - ThromboGenics NV : * To explore strategic options for the company * Decision to increase the company's ability to realize the significant commercial potential of jetrea in the US * Thr.br-says the board has retained Morgan Stanley to help with the strategic review process
BRUSSELS Feb 24 (Reuters) - ThromboGenics NV : * To explore strategic options for the company * Decision to increase the company's ability to realize the significant commercial potential of jetrea in the US * Thr.br-says the board has retained Morgan Stanley to help with the strategic review process
via Smart Health Shop Forum http://ift.tt/1fwXPMF
No comments:
Post a Comment